[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-416702-105":59,"doc-detail-416702-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","disentangling-patient-disease-and-treatment-effects-proteomic-and-metabolomic-differences-in-early-versus-established-psoriatic-arthritis-clinical-science","Disentangling patient, disease, and treatment effects - proteomic and metabolomic differences in early versus established psoriatic arthritis - Clinical science","","Psoriatic arthritis is an inflammatory, heterogeneous condition with unclear mechanisms, and biological processes may shift with disease progression or therapy. This study distinguishes proteomic and metabolomic signatures between DMARD-naïve and DMARD-failing patients. Using baseline data from 40 DMARD-naïve and 40 DMARD-failing participants in the TOFA-PREDICT trial, investigators compared molecular profiles and assessed mediation by patient, disease, and treatment factors. Results identified 36 proteins and 25 metabolites differing between groups, largely independent of clinical characteristics or medication.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/disentangling-patient-disease-and-treatment-effects-proteomic-and-metabolomic-differences-in-early-versus-established-psoriatic-arthritis-clinical-science/416702/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/disentangling-patient-disease-and-treatment-effects-proteomic-and-metabolomic-differences-in-early-versus-established-psoriatic-arthritis-clinical-science/416702.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To identify differences in proteomic and metabolomic profiles between DMARD-naïve and DMARD-failing psoriatic arthritis patients, and to evaluate whether these differences are mediated by patient, disease, and treatment characteristics.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the patient groups defined in the analysis?",{"text":117,"@type":113},"The discovery cohort included baseline data from 40 DMARD-naïve and 40 DMARD-failing PsA patients with active disease, all meeting the Classification Criteria for Psoriatic Arthritis.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular differences were found between DMARD-naïve and DMARD-failing patients?",{"text":121,"@type":113},"The study identified 36 proteins and 25 metabolites that differentiated DMARD-naïve from DMARD-failing PsA patients. Most differences were independent of clinical characteristics and medication use, though some were (partly) mediated by measures such as PASI and inflammatory markers.",{"name":123,"@type":110,"acceptedAnswer":124},"What do the findings suggest for patient care or monitoring?",{"text":125,"@type":113},"Different molecular patterns may characterize distinct phases of psoriatic arthritis. If confirmed in larger studies, this knowledge could support better patient stratification and help identify specific treatment needs or improve monitoring.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},416702,1791294761,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46,"preview_page_count":4},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Clinical science  \nDisentangling patient, disease, and treatment effects: proteomic and metabolomic differences in early versus established psoriatic arthritis  \nMieke L.M. Bentvelzen 1, 􀀃 , Said el Bouhaddani 2, Julia Spierings 1, Harald E. Vonkeman 3, Shasti C. Mooij 3, Lydia G. Schipper 4, Amin Herman5, Simon C. Mastbergen 1,  \nHae-Won Uh 2, Paco M.J. Welsing 1  \n1 Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands 2 Department of Data Science and Biostatistics, div. Julius Centrum, University Medical Center Utrecht, Utrecht, The Netherlands 3 Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital, Enschede, The Netherlands 4 Department of Rheumatology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands  \n5 Department of Rheumatology, Antonius Hospital, Utrecht, The Netherlands  \n􀀃 Correspondence to: M. L. M. Bentvelzen, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Postbus 85090, 3508 GA Utrecht, The [Netherlands. E-mail: m.l.m.bentvelzen@umcutrecht.nl](Netherlands. E-mail: m.l.m.bentvelzen@umcutrecht.nl)  \nAbstract  \nObjectives: Psoriatic arthritis is a heterogeneous inflammatory disease with unclear pathobiology. Biological mechanisms may change overtime with disease progression or treatment and may correlate with specific characteristics of PsA. This study aimed to identify differences in proteomic and metabolomic profiles between DMARD-naïve (DN) and DMARD-failing (DF) PsA patients.  \nMethods: In the TOFA-PREDICT trial discovery cohort, baseline data from 40 DN and 40 DF PsA patients with active disease (all fulfilling the Classification Criteria for Psoriatic Arthritis) were analysed. The aim was to identify differences in proteomic and metabolomic profiles using univariate (Welch’s t-test) and multivariate (XGBoost and sPLS-DA) approaches; potential mediation of these differences by patient, disease and treatment characteristics; and biological functions of identified markers through enrichment analysis.  \nResults: A total of 36 proteins and 25 metabolites differentiated DN from DF PsA patients. Mediation analysis indicated that most differences are independent of clinical characteristics or current use of medication. Eleven proteins and two metabolites were (partially) mediated by the Psoriasis Area and Severity Index, CRP level, ESR, tender joint count 68, disease duration or smoking. Enrichment analysis highlighted an overrepresentation of immune and inflammatory proteins, while metabolomic markers were predominantly glycerophospholipids, with no significant pathway enrichment.  \nConclusion: This study reveals distinct proteomic and metabolomic profiles between DN and DF PsA patients and highlights markers potentially involved in PsA pathogenesis. These findings emphasise the biological heterogeneity of PsA patients and the need to consider the disease phase in proteomic and metabolomic analysis.  \nTrial registration: EU Clinical Trials Register ([http://www.clinicaltrialsregister.eu/](http://www.clinicaltrialsregister.eu/)), 2017-003900-28 .  \nLay Summary  \nWhat does this mean for patients?  \nPsoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin. Patients are affected by PsA in different ways and the disease is still not fully understood. In this study we compared two groups of patients with active PsA on a molecular level. One group had never taken disease-modifying medicines, while the other group had tried these medicines, but their disease had not improved sufficiently. Blood samples from both groups were analysed to measure proteins and metabolites (small molecules) . Differences in 36 proteins and 25 metabolites were found between the two patient groups. Most of these differences could not be explained by age, sex or clinical and disease characteristics. These findings suggest that people at different stage","cbCaiod1MbVan5Sq","https://ap.wps.com/l/cbCaiod1MbVan5Sq","pdf",1150922,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Lay Summary\n## What does this mean for patients?\n# Key message\n# Keywords","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To identify differences in proteomic and metabolomic profiles between DMARD-naïve and DMARD-failing psoriatic arthritis patients, and to evaluate whether these differences are mediated by patient, disease, and treatment characteristics.\"},{\"question\":\"How were the patient groups defined in the analysis?\",\"answer\":\"The discovery cohort included baseline data from 40 DMARD-naïve and 40 DMARD-failing PsA patients with active disease, all meeting the Classification Criteria for Psoriatic Arthritis.\"},{\"question\":\"Which molecular differences were found between DMARD-naïve and DMARD-failing patients?\",\"answer\":\"The study identified 36 proteins and 25 metabolites that differentiated DMARD-naïve from DMARD-failing PsA patients. Most differences were independent of clinical characteristics and medication use, though some were (partly) mediated by measures such as PASI and inflammatory markers.\"},{\"question\":\"What do the findings suggest for patient care or monitoring?\",\"answer\":\"Different molecular patterns may characterize distinct phases of psoriatic arthritis. If confirmed in larger studies, this knowledge could support better patient stratification and help identify specific treatment needs or improve monitoring.\"}]","Disentangling patient, disease, and treatment effects - proteomic and metabolomic differences in early versus established psoriatic arthritis - Clinical science | PDF",1790606418]